Britain and America have announced a significant trade agreement that will maintain no tariffs on UK pharmaceutical shipments entering the US market.
The Terms of the Accord
Under the terms of the agreement, the UK has pledged to raise funding on drugs through the NHS. This commitment guarantees that duties on these crucial exports will remain at zero for a period of three years.
This agreement comes after recent statements to hike tariffs on patented pharmaceutical imports, with potential rates discussed reaching double the cost.
"This arrangement between the United Kingdom bolsters the global environment for cutting-edge drugs and introduces much-needed fairness to transatlantic medicine commerce," a statement said.
Economic Importance
Pharmaceuticals constitute one of the UK's biggest exports to the United States, which is easily the biggest buyer for leading UK drugmakers.
Trade data reveal that in the one-year period leading up to the third quarter, the UK exported pharmaceutical products worth billions to the US. This amount made up 17.4% of British export trade in that period.
"This agreement protects employment, boosts capital expenditure and facilitates the UK to establish itself as a international leader for medical research," the Business and Trade Secretary stated.
Key UK Commitments
The pact includes several key commitments from the British government:
- Revised Affordability Limit: The UK will raise the cost ceiling at which it judges new medicines to be unaffordable by 25%.
- Increased NHS Spending: There is a target to double overall health service expenditure on medicines from 0.3% of Gross Domestic Product to 0.6% over the next decade.
- Refund Ceiling: The sum pharmaceutical firms must return to the NHS to prevent overspending will be restricted at 15%. In the past, refunds were more than 20%.
Recent Tensions
The deal takes place against a ongoing dispute between the pharmaceutical industry and the UK government over medicine costs and NHS adoption.
This friction were exacerbated by claims that American customers were charged several times more for the same drugs than patients in the Britain and the EU.
Recently, several large drug company projects in the UK have been delayed or abandoned, while substantial investments have been pledged toward projects in the United States.
One official stated that the NHS had to invest a greater share on drugs, noting that its expenditure on drugs had shrunk as a share of its resources over the previous ten-year period.
